The TRA 2P–TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events—Thrombolysis in Myocardial Infarction 50) clinical trial enrolled patients who had a history of atherosclerosis within the previous 2 weeks to 12 months (190). The gene discussed is F2R; the disease is atherosclerosis.